<?xml version="1.0" encoding="UTF-8"?>
<!--generator='jetpack-16.4'-->
<!--Jetpack_Sitemap_Buffer_News_XMLWriter-->
<?xml-stylesheet type="text/xsl" href="//pharminent.com/news-sitemap.xsl"?>
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:news="http://www.google.com/schemas/sitemap-news/0.9" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.sitemaps.org/schemas/sitemap/0.9 http://www.sitemaps.org/schemas/sitemap/0.9/sitemap.xsd">
 <url>
  <loc>https://pharminent.com/fda-approves-roches-oral-serd-wilserdly-for-breast-cancer/</loc>
  <lastmod>2026-11-17T12:46:01Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>Pharminent</news:name>
    <news:language>en</news:language>
   </news:publication>
   <news:title>FDA approves Roche&amp;#039;s oral SERD Wilserdly for breast cancer</news:title>
   <news:publication_date>2026-11-17T12:46:01Z</news:publication_date>
   <news:genres>Blog</news:genres>
  </news:news>
 </url>
 <url>
  <loc>https://pharminent.com/week-in-review/week-in-review-intelligence-brief-november-16-2026/</loc>
  <lastmod>2026-11-16T21:47:03Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>Pharminent</news:name>
    <news:language>en</news:language>
   </news:publication>
   <news:title>Week in Review • INTELLIGENCE BRIEF • November 14, 2026</news:title>
   <news:publication_date>2026-11-16T21:47:03Z</news:publication_date>
   <news:genres>Blog</news:genres>
  </news:news>
 </url>
 <url>
  <loc>https://pharminent.com/strategic-news-watch/strategic-news-watch-november-16-2026/</loc>
  <lastmod>2026-11-16T21:46:23Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>Pharminent</news:name>
    <news:language>en</news:language>
   </news:publication>
   <news:title>Strategic News Watch • November 16, 2026</news:title>
   <news:publication_date>2026-11-16T21:46:23Z</news:publication_date>
   <news:genres>Blog</news:genres>
  </news:news>
 </url>
 <url>
  <loc>https://pharminent.com/fda-declines-to-approve-summits-ivonescimab-in-lung-cancer/</loc>
  <lastmod>2026-11-16T12:45:38Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>Pharminent</news:name>
    <news:language>en</news:language>
   </news:publication>
   <news:title>FDA declines to approve Summit&amp;#039;s ivonescimab in lung cancer</news:title>
   <news:publication_date>2026-11-16T12:45:38Z</news:publication_date>
   <news:genres>Blog</news:genres>
  </news:news>
 </url>
 <url>
  <loc>https://pharminent.com/strategic-news-watch/strategic-news-watch-november-13-2026/</loc>
  <lastmod>2026-11-16T12:24:17Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>Pharminent</news:name>
    <news:language>en</news:language>
   </news:publication>
   <news:title>Strategic News Watch • November 13, 2026</news:title>
   <news:publication_date>2026-11-16T12:24:17Z</news:publication_date>
   <news:genres>Blog</news:genres>
  </news:news>
 </url>
 <url>
  <loc>https://pharminent.com/glp-1-competitive-market/glp-1-competitive-market-digest-weekly-november-13-2026/</loc>
  <lastmod>2026-11-15T15:31:46Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>Pharminent</news:name>
    <news:language>en</news:language>
   </news:publication>
   <news:title>GLP-1 Competitive Market Digest • Weekly • November 13, 2026</news:title>
   <news:publication_date>2026-11-15T15:31:46Z</news:publication_date>
   <news:genres>Blog</news:genres>
  </news:news>
 </url>
 <url>
  <loc>https://pharminent.com/oncology/oncology-intelligence-digest-november-13-2026/</loc>
  <lastmod>2026-11-15T15:31:38Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>Pharminent</news:name>
    <news:language>en</news:language>
   </news:publication>
   <news:title>Oncology Intelligence Digest • November 13, 2026</news:title>
   <news:publication_date>2026-11-15T15:31:38Z</news:publication_date>
   <news:genres>Blog</news:genres>
  </news:news>
 </url>
</urlset>
